Cidara Therapeutics, Inc. (CDTX)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $2.2M
- Dec 10 · Unusual
- Form 4 sales
- 37
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planMar 11 2024
Sold 20,662 shares at $0.67 ($14k)
Sandison Taylor, Chief Medical Officer
No 10b5-1 planSold 5.6% of holdings ($246k position)347,095 shares left1.1x usual sizeFiling
- 2 Form 4 saleNo planMar 11 same day
Sold 21,029 shares at $0.67 ($14k)
Tari Leslie, CHIEF SCIENTIFIC OFFICER
No 10b5-1 planSold 7.5% of holdings ($187k position)258,681 shares left1.4x usual sizeFiling
- 3 Form 4 saleNo planSep 11 +184 days
Sold 909 shares at $11.64 ($11k)
Tari Leslie, CHIEF SCIENTIFIC OFFICER
No 10b5-1 planSold 4.9% of holdings ($218k position)17,788 shares left0.1x usual sizeFiling
- 4 Form 4 saleNo planSep 11 same day
Sold 924 shares at $11.64 ($11k)
Sandison Taylor, Chief Medical Officer
No 10b5-1 planSold 3.9% of holdings ($279k position)23,067 shares left0x usual sizeFiling
- 5 Form 4 saleNo planMar 11 +181 days
Sold 1,773 shares at $21.96 ($39k)
Tari Leslie, CHIEF SCIENTIFIC OFFICER
No 10b5-1 planSold 9.9% of holdings ($395k position)16,215 shares left0.1x usual sizeFiling
- 6 Form 4 saleNo planMar 11 same day
Sold 1,664 shares at $21.96 ($37k)
Ward Shane, COO & CLO
No 10b5-1 planSold 10.2% of holdings ($359k position)14,674 shares leftFiling
- 7 Form 4 saleNo planSep 11 +184 days
Sold 474 shares at $62.86 ($30k)
Davarpanah Nicole Negar, Chief Medical Officer
No 10b5-1 planSold 1.5% of holdings ($2M position)31,418 shares leftFirst sale on recordFiling
- 8 Form 4 saleUnusualDec 10 +90 days
Sold 9,959 shares at $220.08 ($2.2M)
Ward Shane, COO & CLO
No 10b5-1 planSold 28.5% of holdings ($7.7M position)25,033 shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (37)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Ward Shane | COO & CLO | Form 4 sale | 9,959 | $2.2M | 28.5% | Unusual | SEC |
| Sep 11, 2025 | Davarpanah Nicole Negar | Chief Medical Officer | Form 4 sale | 474 | $30k | 1.5% | No plan | SEC |
| Mar 11, 2025 | Ward Shane | COO & CLO | Form 4 sale | 1,664 | $37k | 10.2% | No plan | SEC |
| Mar 11, 2025 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 1,773 | $39k | 9.9% | No plan | SEC |
| Sep 11, 2024 | Sandison Taylor | Chief Medical Officer | Form 4 sale | 924 | $11k | 3.9% | No plan | SEC |
| Sep 11, 2024 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 909 | $11k | 4.9% | No plan | SEC |
| Mar 11, 2024 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 21,029 | $14k | 7.5% | No plan | SEC |
| Mar 11, 2024 | Sandison Taylor | Chief Medical Officer | Form 4 sale | 20,662 | $14k | 5.6% | No plan | SEC |
| Mar 11, 2024 | Ward Shane | COO & CLO | Form 4 sale | 20,473 | $14k | 9.3% | No plan | SEC |
| Mar 11, 2024 | Shah Preetam | CFO & CBO | Form 4 sale | 18,931 | $13k | 7.7% | No plan | SEC |
| Sep 11, 2023 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 18,469 | $18k | 6.3% | No plan | SEC |
| Sep 11, 2023 | Sandison Taylor | Chief Medical Officer | Form 4 sale | 18,793 | $18k | 4.9% | No plan | SEC |
| Mar 13, 2023 | Ward Shane | COO & CLO | Form 4 sale | 4,329 | $7k | 4.9% | Plan not stated | SEC |
| Mar 13, 2023 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 7,562 | $12k | 3.8% | Plan not stated | SEC |
| Mar 13, 2023 | Shah Preetam | CFO & CBO | Form 4 sale | 6,648 | $10k | 4.3% | Plan not stated | SEC |
| Mar 13, 2023 | Sandison Taylor | Chief Medical Officer | Form 4 sale | 7,203 | $11k | 2.4% | Plan not stated | SEC |
| Jan 12, 2023 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 11,814 | $14k | 88.8% | Unusual | SEC |
| Sep 19, 2022 | Shah Preetam | CFO & CBO | Form 4 sale | 15,642 | $12k | 9.4% | Plan not stated | SEC |
| Sep 12, 2022 | Sandison Taylor | Chief Medical Officer | Form 4 sale | 18,478 | $13k | 6.0% | Plan not stated | SEC |
| Sep 12, 2022 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 18,159 | $12k | 8.6% | Plan not stated | SEC |
| Sep 12, 2022 | Daruwala Paul | Chief Operating Officer | Form 4 sale | 16,199 | $11k | 6.8% | Plan not stated | SEC |
| Mar 21, 2022 | Johnson Brady | Vice President, Finance | Form 4 sale | 654 | $530 | 1.3% | Plan not stated | SEC |
| Mar 11, 2022 | Johnson Brady | Vice President, Finance | Form 4 sale | 945 | $671 | 1.9% | Plan not stated | SEC |
| Jan 5, 2022 | Daruwala Paul | Chief Operating Officer | Form 4 sale | 5,133 | $6k | 2.7% | Plan not stated | SEC |
| Jan 5, 2022 | Johnson Brady | Vice President, Finance | Form 4 sale | 416 | $520 | 0.8% | Plan not stated | SEC |
| Jan 5, 2022 | Tari Leslie | Chief Scientific Officer | Form 4 sale | 1,252 | $2k | 0.8% | Plan not stated | SEC |
| Apr 1, 2021 | Abdollahian Neil | Chief Business Officer | Form 4 sale | 4,337 | $10k | 7.0% | Plan not stated | SEC |
| Apr 1, 2021 | Daruwala Paul | Chief Operating Officer | Form 4 sale | 3,461 | $7k | 6.4% | Plan not stated | SEC |
| Apr 1, 2021 | Oien Jessica | General Counsel & Secretary | Form 4 sale | 2,001 | $5k | 20.5% | Plan not stated | SEC |
| Jan 3, 2020 | Abdollahian Neil | Chief Business Officer | Form 4 sale | 2,340 | $8k | 4.4% | Plan not stated | SEC |
| Jan 3, 2020 | Daruwala Paul | Chief Operating Officer | Form 4 sale | 2,340 | $8k | 4.2% | Plan not stated | SEC |
| Jan 2, 2020 | Oien Jessica | General Counsel & Secretary | Form 4 sale | 834 | $3k | 10.7% | Plan not stated | SEC |
| Oct 2, 2019 | Daruwala Paul | Chief Operating Officer | Form 4 sale | 3,295 | $6k | 5.6% | Plan not stated | SEC |
| Oct 1, 2019 | Abdollahian Neil | Chief Business Officer | Form 4 sale | 7,284 | $14k | 12.8% | Plan not stated | SEC |
| Sep 27, 2019 | Oien Jessica | General Counsel & Secretary | Form 4 sale | 1,001 | $2k | 11.4% | Plan not stated | SEC |
| Mar 8, 2019 | Abdollahian Neil | Chief Business Officer | Form 4 sale | 2,300 | $6k | 7.0% | Plan not stated | SEC |
| Mar 7, 2019 | Daruwala Paul | Chief Operating Officer | Form 4 sale | 2,240 | $6k | 4.3% | Plan not stated | SEC |